Rise Advisors LLC Boosts Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Rise Advisors LLC boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 562 shares of the company’s stock after purchasing an additional 21 shares during the period. Rise Advisors LLC’s holdings in IDEXX Laboratories were worth $301,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Red Spruce Capital LLC increased its holdings in shares of IDEXX Laboratories by 1.1% in the second quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock worth $912,000 after purchasing an additional 19 shares during the period. Sage Mountain Advisors LLC grew its stake in shares of IDEXX Laboratories by 3.8% during the first quarter. Sage Mountain Advisors LLC now owns 635 shares of the company’s stock valued at $267,000 after buying an additional 23 shares during the last quarter. Great Lakes Advisors LLC boosted its holdings in shares of IDEXX Laboratories by 0.9% during the first quarter. Great Lakes Advisors LLC now owns 2,567 shares of the company’s stock worth $1,078,000 after purchasing an additional 23 shares during the period. PDS Planning Inc boosted its holdings in shares of IDEXX Laboratories by 3.9% during the first quarter. PDS Planning Inc now owns 641 shares of the company’s stock worth $269,000 after purchasing an additional 24 shares during the period. Finally, King Luther Capital Management Corp boosted its holdings in shares of IDEXX Laboratories by 0.5% during the first quarter. King Luther Capital Management Corp now owns 4,896 shares of the company’s stock worth $2,056,000 after purchasing an additional 24 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on IDXX. BTIG Research raised their price objective on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. JPMorgan Chase & Co. raised their price target on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a research report on Monday, August 4th. Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 target price for the company. Finally, Piper Sandler reissued a “neutral” rating and set a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $649.44.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 7,143 shares of the firm’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total value of $4,503,161.49. Following the completion of the transaction, the executive vice president owned 18,007 shares of the company’s stock, valued at approximately $11,352,153.01. This trade represents a 28.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director M Anne Szostak sold 2,187 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the transaction, the director directly owned 262 shares of the company’s stock, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 54,057 shares of company stock valued at $34,293,468. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $641.14 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The firm has a market capitalization of $51.29 billion, a P/E ratio of 53.38, a price-to-earnings-growth ratio of 4.15 and a beta of 1.56. The company’s 50-day moving average is $603.59 and its 200 day moving average is $514.19. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the firm earned $2.44 EPS. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.